



Patent Application of HISCOTT, John et al

Serial No. 09/647,965

Group Art Unit: 1636

Filed: October 6, 2000

Examiner: Terry A. McKelvey

For: HIGHLY ACTIVE FORMS OF INTERFERON REGULATORY FACTOR PROTEINS

### INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement is being filed in the manner prescribed by 37 CFR 1.97(b) - (d) to satisfy the duty under 37 CFR 1.56 to disclose to the Office information, known to individuals associated with the filing and prosecution of the subject application, which is material to the examination of the application.

In accordance with 37 CFR 1.97(g) and (h), this statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 CFR 1.56(b).

This Information Disclosure Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing date of a first official action on the merits; or before the mailing of a first official action after the filing of a request for continued examination under 37 CFR 1.114; and therefore applicant respectfully requests consideration under 37 CFR 1.97(b).

In compliance with 37 CFR 1.98(a)(2), also enclosed is a legible copy of:

- i) each United States and foreign patent;
- ii) each publication or that portion which caused it to be listed; and
- iii) all other information or that portion which caused it to be listed, excluding any copies of a United States patent application.

The enclosed publication was cited during prosecution of the corresponding European Patent application No. 99 914 389.4

In compliance with 37 CFR 1.98(a)(1), a list of all patents, publications, applications or other information submitted for consideration by the Office is hereby provided by way of the attached Form PTO-1449.

It is respectfully requested that the information be expressly considered by the Examiner and that the references be made of record and appear among the "References Cited" on any patent to issue therefrom.

The Patent Office is hereby authorized to charge any deficiency, or credit any overpayment in fees to Deposit Account Number 19-2550.


Respectfully submitted,

JOHN HISCOTT, ET AL

Dated: June 17, 2005

  
Elizabeth A. Hayes-Quebec  
Reg. No. 48,305

Encls.:      Form PTO-1449  
              All references listed on Form PTO-1449  
              Acknowledgement Card

<b>Form PTO-1449 (Modified)</b>  <b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		Atty. Docket No. A33606-PCT- USA-071235.0111	Serial No. 09/647,965
		Applicant HISCOTT, John et al	
		Filing Date October 6, 2000	Group 1636

**REFERENCE DESIGNATION U.S. PATENT DOCUMENTS**

EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
					YES	NO

**OTHER ART (including Author, Title, Date, Pertinent Pages, Etc.)**

AA		Sato, Mitsuharu et al; POSITIVE FEEDBACK REGULATION OF TYPE I IFN GENES BY THE IFN-INDUCIBLE TRANSCRIPTION FACTOR IRF-7; Federation of European Biochemical Societies Letters 441 (1998) pgs. 106-110.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.